BioTissue Holdings Refocuses on Eye Care Innovation with Business Sale
BioTissue Holdings Strengthens Focus on Ocular Innovation
In a strategic move to enhance its dedication to the ocular sector, BioTissue Holdings, Inc. has finalized the sale of its surgical and wound care business to BioStem Technologies, Inc. This transaction marks a pivotal moment for BioTissue, allowing the company to streamline its operations and concentrate on developing advanced therapies for eye conditions.
The Details of the Sale
On January 21, 2026, BioTissue announced that it had completed the transfer of its non-ocular surgical and wound care business, which includes the Neox® and Clarix® product lines, to BioStem, a renowned MedTech company specializing in placental-derived products. Not only will BioStem gain exclusive rights to these lines, but it will also integrate BioTissue's surgical sales team into its commercial organization. As part of the agreement, BioTissue will continue to manufacture these products for BioStem.
Commitment to Ocular Health
As BioTissue pivots towards ocular innovation, the company aims to enhance its portfolio, focusing on products like Prokera®, CAM360 AmnioGraft™, AmnioGraft®, and AmnioGuard®. This strategic shift is designed to bolster its commitment to interventional therapies for both acute and chronic ocular surface conditions. By prioritizing product innovation and professional education, BioTissue is well-positioned to support eye care professionals in delivering top-quality patient care.
Ted Davis, President and CEO of BioTissue, expressed confidence in this new direction: "Since our founding, our mission has been to transform patient outcomes through regenerative therapies. This divestiture is a catalyst for our next chapter, one focused squarely on eye care innovation." With a streamlined focus, BioTissue expects to deliver breakthrough solutions that can significantly enhance patient outcomes in the ocular field.
BioStem's Vision
BioStem Technologies has a clear vision for its new acquisition. The CEO and Chairman, Jason Matuszewski, highlighted how BioTissue's robust commercial capabilities complement BioStem's existing offerings. He noted the substantial growth opportunity this acquisition presents and emphasized the need to focus on commercial execution to drive positive patient outcomes.
A Legacy of Innovation
BioTissue Holdings has made significant contributions to the field of regenerative medicine, especially in ocular health. By utilizing unique properties of human birth tissue, BioTissue has pioneered products that support the healing of ocular surface issues. With over a million procedures utilizing its products and more than 420 peer-reviewed publications backing its platform technology, the company continues to lead in delivering innovative solutions for healthcare providers.
The firm operates under the proprietary CryoTek® cryopreservation technology, which preserves the structural integrity of the products through advanced processing techniques. Furthermore, BioTissue is actively pursuing Investigational New Drug (IND) applications in hopes of advancing toward Biologic License Applications (BLAs) in an effort to meet unmet clinical needs.
BioTissue's commitment to supporting healthcare professionals is demonstrated through a focus on evidence-based science and continuous innovation, ensuring optimal patient outcomes.
Conclusion
The sale of BioTissue's surgical and wound care services to BioStem Technologies signifies a bold step towards enhancing ocular therapies. As both companies leverage their strengths, they aim to improve patient lives dramatically through advanced medical solutions. BioTissue's future appears bright as it deepens its commitment to ocular health, fostering innovation to meet the evolving needs of eye care professionals and their patients.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.